Multimodal patient state.
For trials, endpoints, and real-world evidence.
Three doors into the substrate.
Find the right patients for your trial faster, with state-vector matching across our hospital partners. Eligibility screening designed for the substrate, not for one inclusion criterion at a time.
Reduce trial cost and time-to-readout with retrospective matched cohorts from qualified institutions. EU-sovereign, audit-ready, fit for regulatory submission discussions.
Capture response across the full patient state : not single timepoints. Generate real-world evidence with the granularity your protocol needs and the documentation your auditor expects.
Engagement modes.
Substrate-as-a-service for trial enrichment · Co-developed virtual control arm projects · RWE generation for selected indications.
Built for the questions you actually ask.
Honest scope.
Hale-X partners with selected pharma and CRO organizations on a project basis. We are not a productized pharma platform : we are a clinical substrate that selected sponsors can engage with under tailored agreements. If your indication aligns with our active clinical pipeline, we'd like to talk.